David Rosenberg

Samuel Gershon

This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications. Third edition of the first ever book published on pediatric psychopharmacology from renowned editors. Incorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior. Addresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD. Features many tables, figures and pictorials, making it highly accessible and reader friendly.

Pharmacotherapy of Child and Adolescent Psychiatric Disorders

Bernard Lerer

This book is presented as a 1989 update on the task set by Robert Burton in his "Anatomy ofMelancholy," published in 1621. Burton's treatise addressed ques tions regarding depression which are still highly relevant today: ." . . What is it, with all the kinds, causes, symptoms, prognostickes and several cures ofit. . . . " These remain the core issues in affective disorders notwithstanding the remarkable progress that has been made in addressing them. New Directions in Affective Disorders sets out to provide an overviewofwhat has been achieved with particular emphasison developing trends and novel initiatives in bothfundamental research and treatment. The overriding objective of the book is to integrate significant contributions from basic and clinical science into a comprehensive format which will be of value to both clinicians and researchers. Intensive interest in affective illness isan inevitableconsequenceofthe frequency with which these disorders occur. Depression is the most common psychiatric condition, affecting as many as 50%ofpeople in Western countries at some time in their lives. National Institute ofMental Health Statistics estimate that 15% of adults between 18 and 74 years ofage may be suffering from serious depressive disorders in any given year. Depression is a serious condition with a high mortality. A suicide rate ofapproximately 20,000 deaths per year as a result of this illness is almost certainly a conservative estimate."

New Directions in Affective Disorders

Jair C. Soares

This volume examines attempts to identify genetic risk factors and environmental components contributing to the development of psychiatric disorders. It explores the symptoms, courses, outcomes, treatment responses and aetiologies of a range of psychiatric illnesses to improve disease classification schemes.

Handbook of Medical Psychiatry

The Second Edition of Pharmacotherapy for Child and Adolescent Psychiatric Disorders contains new and expanded chapters on combination therapy pharmacoepidemiology pharmacoeconomics current social, ethical, and legal issues surrounding the administration of psychostimulants and antidepressants to children and teenagers serotonin reuptake inhibitors and discusses techniques to select the most appropriate drug and dosing schedule methods to adjust safely and tailor medical treatments for children during various stages of growth and development the effect of psychoactive drugs on cardiac function Offering nearly 3000 contemporary references to facilitate further research, Pharmacotherapy for Child and Adolescent Psychiatric Disorders, Second Edition is a timely and authoritative guide suitable for psychiatrists, psychologists, pediatricians, pharmaceutical and behavioral scientists, clinical neurologists, primary care physicians, social workers, and graduate and medical school students in these disciplines.

Samuel Gershon

About

Books

Join the club